Analysis Verifies Adverse Effects of T-DX for HER2-Low BC.

Published Date: 16 May 2023

Trastuzumab deruxtecan is used to treat HER2-low metastatic breast cancer, and a safety analysis following a randomized phase 3 trial confirms that patients who take it frequently experience nausea and vomiting.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence

2.

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

3.

24 months after radical prostateectomy, no PSA recurrence was observed when using apalutamide plus ADT.

4.

Modified personalized cancer vaccine generates powerful immune response

5.

Spouses of Cancer Patients May Be at Increased Risk of Suicide


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot